Lipidomics studies on macrophages - bone marrow-derived macrophages treated with 25-hydroxy-cholesterol +/- lipid-depleted media containing compactin
Introduction | Browse | DownloadMouse-over the above links for more information
Treatment details
| LM ID | Analyte | Treatment | Time(hrs) | Sample ID | Value | Units |
|---|---|---|---|---|---|---|
| LMFA01030157 | 5,8,11-eicosatrienoic acid | Lipid-depleted/compactin | 0.0 | BCD100427B002 | 0.3 | pmol/sample |
| LMFA01030157 | 5,8,11-eicosatrienoic acid | Lipid-depleted/compactin | 0.5 | BCD100427B005 | 0.35 | pmol/sample |
| LMFA01030157 | 5,8,11-eicosatrienoic acid | Lipid-depleted/compactin | 1.0 | BCD100427B009 | 0.2 | pmol/sample |
| LMFA01030157 | 5,8,11-eicosatrienoic acid | Lipid-depleted/compactin | 2.0 | BCD100427B013 | 0.45 | pmol/sample |
| LMFA01030157 | 5,8,11-eicosatrienoic acid | Lipid-depleted/compactin | 4.0 | BCD100427B017 | 0.53 | pmol/sample |
| LMFA01030157 | 5,8,11-eicosatrienoic acid | Lipid-depleted/compactin | 8.0 | BCD100427B021 | 0.64 | pmol/sample |
| LMFA01030157 | 5,8,11-eicosatrienoic acid | Lipid-depleted/compactin | 12.0 | BCD100427B025 | 0.1 | pmol/sample |
| LMFA01030157 | 5,8,11-eicosatrienoic acid | Lipid-depleted/compactin | 24.0 | BCD100427B029 | 2.78 | pmol/sample |
| LMFA01030157 | 5,8,11-eicosatrienoic acid | C | 0.0 | BCD100427B001 | 0.38 | pmol/sample |
| LMFA01030157 | 5,8,11-eicosatrienoic acid | C | 0.5 | BCD100427B003 | 0.65 | pmol/sample |
| LMFA01030157 | 5,8,11-eicosatrienoic acid | C | 1.0 | BCD100427B007 | - | pmol/sample |
| LMFA01030157 | 5,8,11-eicosatrienoic acid | C | 2.0 | BCD100427B011 | 0.97 | pmol/sample |
| LMFA01030157 | 5,8,11-eicosatrienoic acid | C | 4.0 | BCD100427B015 | 0.35 | pmol/sample |
| LMFA01030157 | 5,8,11-eicosatrienoic acid | C | 8.0 | BCD100427B019 | 2.18 | pmol/sample |
| LMFA01030157 | 5,8,11-eicosatrienoic acid | C | 12.0 | BCD100427B023 | 0.83 | pmol/sample |
| LMFA01030157 | 5,8,11-eicosatrienoic acid | C | 24.0 | BCD100427B027 | 1.11 | pmol/sample |
| LMFA01030157 | 5,8,11-eicosatrienoic acid | 25OH-Chol + Lipid-depleted/compactin | 0.5 | BCD100427B006 | - | pmol/sample |
| LMFA01030157 | 5,8,11-eicosatrienoic acid | 25OH-Chol + Lipid-depleted/compactin | 1.0 | BCD100427B010 | - | pmol/sample |
| LMFA01030157 | 5,8,11-eicosatrienoic acid | 25OH-Chol + Lipid-depleted/compactin | 2.0 | BCD100427B014 | 0.23 | pmol/sample |
| LMFA01030157 | 5,8,11-eicosatrienoic acid | 25OH-Chol + Lipid-depleted/compactin | 4.0 | BCD100427B018 | 1.32 | pmol/sample |
| LMFA01030157 | 5,8,11-eicosatrienoic acid | 25OH-Chol + Lipid-depleted/compactin | 8.0 | BCD100427B022 | 1.91 | pmol/sample |
| LMFA01030157 | 5,8,11-eicosatrienoic acid | 25OH-Chol + Lipid-depleted/compactin | 12.0 | BCD100427B026 | 0.51 | pmol/sample |
| LMFA01030157 | 5,8,11-eicosatrienoic acid | 25OH-Chol + Lipid-depleted/compactin | 24.0 | BCD100427B030 | 1.2 | pmol/sample |
| LMFA01030157 | 5,8,11-eicosatrienoic acid | 25OH-Chol | 0.5 | BCD100427B004 | - | pmol/sample |
| LMFA01030157 | 5,8,11-eicosatrienoic acid | 25OH-Chol | 1.0 | BCD100427B008 | 0.5 | pmol/sample |
| LMFA01030157 | 5,8,11-eicosatrienoic acid | 25OH-Chol | 2.0 | BCD100427B012 | 0.73 | pmol/sample |
| LMFA01030157 | 5,8,11-eicosatrienoic acid | 25OH-Chol | 4.0 | BCD100427B016 | 0.28 | pmol/sample |
| LMFA01030157 | 5,8,11-eicosatrienoic acid | 25OH-Chol | 8.0 | BCD100427B020 | 0.24 | pmol/sample |
| LMFA01030157 | 5,8,11-eicosatrienoic acid | 25OH-Chol | 12.0 | BCD100427B024 | 0.32 | pmol/sample |
| LMFA01030157 | 5,8,11-eicosatrienoic acid | 25OH-Chol | 24.0 | BCD100427B028 | 0.54 | pmol/sample |